Valneva Faces Mounting Legal Pressure Following Clinical Trial Setback

Valneva under U.S. legal probe after stock plunge. Phase 3 Lyme vaccine missed statistical goal but showed 73.2% efficacy. CEO eyes FDA negotiation for 2026 submission.

The French biotech firm Valneva is confronting intensified legal scrutiny from U.S. shareholders, adding a new layer of challenge as it navigates the aftermath of a key clinical trial result. A second law firm, Bronstein, Gewirtz & Grossman, has now announced a formal investigation into potential securities law violations, following a similar move by Pomerantz LLP. This development places the company firmly in the crosshairs of American plaintiff attorneys once more.

These legal actions were triggered by a dramatic single-day decline in the company's U.S.-traded shares. On March 23, 2026, Valneva's NASDAQ-listed ADRs plummeted by more than 37 percent. This sell-off occurred immediately after the company disclosed that its vaccine candidate, VLA15, had failed to meet the primary statistical endpoint in its Phase 3 VALOR study. The core allegation from plaintiffs is that Valneva misled investors regarding the true prospects of the trial's success.

A Nuanced Clinical Outcome

Digging deeper into the clinical data reveals a more complex picture than the headline failure suggests. The trial actually demonstrated a clinical efficacy rate of 73.2 percent against Lyme disease—a figure many consider respectable. The statistical shortfall arose from an unexpectedly low infection rate among participants during the study period. This resulted in an insufficient number of cases to achieve the pre-specified statistical confidence interval, despite the vaccine showing a strong effect.

In response, CEO Thomas Lingelbach has framed the path forward with the U.S. Food and Drug Administration (FDA) as a "matter of negotiation." Valneva's strategy is to persuade regulators by presenting the totality of the clinical evidence, hoping to secure approval despite the formal statistical miss. Market observers note that the FDA has historically shown flexibility on statistical thresholds for products addressing areas of significant unmet medical need. The company continues to target a submission for licensure in the second half of 2026.

Financial and Market Strain

The financial and market context adds further pressure. Valneva's ADR price currently hovers around $6.10, lingering close to its 52-week low of $5.43. Technically, the Relative Strength Index (RSI) sits at a deeply oversold level of 14, which could signal potential for a short-term technical rebound. However, the broader biotech sector remains under strain due to elevated market volatility, as measured by the VIX index.

Valneva's financial runway is now under increased observation. For the full year 2026, management forecasts revenue in a range of €155 to €170 million, derived largely from existing product sales. The company's most recent cash position was reported at approximately €110 million. All eyes will be on the quarterly results scheduled for release on May 7, which should provide clarity on whether these funds are sufficient to simultaneously support ongoing clinical development and the escalating costs associated with the U.S. legal proceedings.